Novo Nordisk to Slash Ozempic List Prices by 50% in the U.S. by 2027

Novo Nordisk A/S has announced a significant plan to reduce the list prices of its GLP-1 medications, including the blockbuster drug Ozempic, by up to 50% in the United States starting in 2027. This strategic move comes as the pharmaceutical giant faces intensifying competition in the weight-loss and diabetes market, alongside mounting political and regulatory pressure regarding drug affordability. Following the announcement, shares of Novo Nordisk (NVO) experienced a decline in premarket trading as investors weighed the impact on future revenue streams. While the price reduction aims to broaden patient access and potentially increase sales volume, analysts express concern over the erosion of profit margins for the company's core product line. The decision is also expected to influence the broader GLP-1 market, potentially impacting competitors like Eli Lilly (LLY) and signaling a pivotal shift in the pricing landscape for the healthcare industry.